- Home
- BBAR vs DNLI Comparison
BBAR vs DNLI Comparison
Compare BBAR & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBAR | DNLI |
|---|---|---|
| Founded | 1886 | 2013 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | 1997 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BBAR | DNLI |
|---|---|---|
| Price | $14.23 | $18.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $17.00 | ★ $34.09 |
| AVG Volume (30 Days) | 803.5K | ★ 1.7M |
| Earning Date | 03-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.21 | N/A |
| Revenue Next Year | $13.00 | $188.54 |
| P/E Ratio | $26.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.76 | $10.57 |
| 52 Week High | $23.10 | $23.77 |
Technical Indicators
Market Signals| Indicator | BBAR | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 39.00 |
| Support Level | $13.13 | $13.52 |
| Resistance Level | $17.36 | $18.21 |
| Average True Range (ATR) | 0.82 | 1.19 |
| MACD | 0.21 | -0.29 |
| Stochastic Oscillator | 53.28 | 4.29 |
Price Performance
Historical ComparisonAbout BBAR Banco BBVA Argentina S.A. ADS
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.